Loading...
(177)Lu-DOTATATE and (177)Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment
Patients with radioiodine-refractory differentiated thyroid cancer (RrDTC) have only a limited or no benefit from radioiodine therapy. For these patients, tyrosine kinase inhibitors have demonstrated encouraging results in advanced RrDTC. Nevertheless, these therapies are related with substantial si...
Na minha lista:
| Udgivet i: | World J Nucl Med |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Wolters Kluwer - Medknow
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6945353/ https://ncbi.nlm.nih.gov/pubmed/31933557 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/wjnm.WJNM_112_18 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|